Alvotech SA

Alvotech’s AVT80 PK study meets all primary endpoints, confirming biosimilarity to Entyvio and positioning the company for fast regulatory approvals and market entry.

Alvotech SA successfully lists on Nasdaq Stockholm, marking a strategic expansion and surge in investor confidence, as the biotech company continues to ride the wave of its robust performance in the biosimilar medicines sector.

The FDA has approved Alvotech’s biosimilar SELARSDI as interchangeable with Stelara, a major milestone for the biotech company and a significant step forward for the industry in terms of affordable treatment options.

Alvotech SA is set to unveil its first-quarter financial results on May 8, 2025, amidst rising short interest and market uncertainty, with investors and analysts closely watching for clarity on the company’s future prospects.